Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. - Federico Pulido, María Yllescas, M. A. von Wichmann, J. de Miguel, H. de Mataró, H. del Mar, H. Virgen de las Nieves, Esteban Ribera, M. de Miguel, María Lagarde, Ignacio Pérez-Valero, Rosario Palacios, Antoni Payeras, Pere Domingo, José Sanz - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Oxford University Press, Clinical Infectious Diseases, 12(65), p. 2112-2118, 2017

DOI: 10.1093/cid/cix734

Links

Tools

Export citation

Search in Google Scholar

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

Journal article published in 2017 by Federico Pulido, María Yllescas, M. A. von Wichmann, J. de Miguel, H. de Mataró, H. del Mar, H. Virgen de las Nieves, Esteban Ribera, M. de Miguel, María Lagarde, Ignacio Pérez-Valero, Rosario Palacios, Antoni Payeras, Pere Domingo, José Sanz and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO